{"id":"moxifloxacin-m","safety":{"commonSideEffects":[{"rate":"4-6","effect":"Nausea"},{"rate":"3-5","effect":"Diarrhea"},{"rate":"1-3","effect":"Dizziness"},{"rate":"0.3-1","effect":"Tendinitis/tendon rupture"},{"rate":null,"effect":"QT prolongation"},{"rate":"0.5-1","effect":"Photosensitivity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL1200735","moleculeType":"Small molecule","molecularWeight":"437.90"},"_dailymed":{"setId":"182ecd0f-714f-42f0-9b16-fb604cf15786","title":"MOXIFLOXACIN TABLET, FILM COATED [MACLEODS PHARMACEUTICALS LIMITED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Moxifloxacin binds to and inhibits DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This dual inhibition leads to rapid bactericidal activity against a broad spectrum of aerobic and anaerobic bacteria. It is particularly effective against respiratory pathogens and has enhanced activity against gram-positive organisms compared to earlier fluoroquinolones.","oneSentence":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:08.907Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired bacterial pneumonia"},{"name":"Acute bacterial sinusitis"},{"name":"Acute bacterial exacerbation of chronic bronchitis"},{"name":"Uncomplicated skin and soft tissue infections"},{"name":"Complicated skin and soft tissue infections"},{"name":"Intra-abdominal infections"},{"name":"Tuberculosis (drug-resistant forms)"}]},"trialDetails":[{"nctId":"NCT06253715","phase":"PHASE3","title":"Shortened Regimen for Drug-susceptible TB in Children","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-01-15","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node","enrollment":860},{"nctId":"NCT07170800","phase":"PHASE2","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","status":"RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2025-09-19","conditions":"Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":60},{"nctId":"NCT04722978","phase":"PHASE3","title":"Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2021-04-20","conditions":"Triple Negative Breast Cancer","enrollment":228},{"nctId":"NCT05114720","phase":"PHASE3","title":"Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-11-11","conditions":"Breast Cancer","enrollment":559},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT06107036","phase":"PHASE1","title":"A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-06","conditions":"Healthy","enrollment":46},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT06649942","phase":"PHASE1","title":"A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults","status":"COMPLETED","sponsor":"Kaken Pharmaceutical","startDate":"2024-10-01","conditions":"Healthy Volunteers - Male and Female","enrollment":40},{"nctId":"NCT07126639","phase":"NA","title":"A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-01","conditions":"Efficacy and Safety","enrollment":200},{"nctId":"NCT04179500","phase":"PHASE2","title":"A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2021-09-16","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":26},{"nctId":"NCT04856644","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2020-01-01","conditions":"Tuberculosis, Pulmonary","enrollment":333},{"nctId":"NCT02589782","phase":"PHASE2, PHASE3","title":"Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2017-01","conditions":"Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis, Tuberculosis, Pulmonary","enrollment":552},{"nctId":"NCT04207112","phase":"PHASE2, PHASE3","title":"Economic Evaluation of New MDR TB Regimens","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2020-10-20","conditions":"Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis, Pulmonary Tuberculoses","enrollment":73},{"nctId":"NCT05381194","phase":"PHASE4","title":"BPaL(M) Regimen for the Treatment of MDR/RR-TB","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-12-13","conditions":"Multidrug- and Rifampicin-resistant Tuberculosis","enrollment":80},{"nctId":"NCT03934203","phase":"PHASE1","title":"This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-05-09","conditions":"Healthy","enrollment":47},{"nctId":"NCT03338621","phase":"PHASE2, PHASE3","title":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2018-07-30","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":455},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT04563845","phase":"PHASE1","title":"Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-11-09","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT02409290","phase":"PHASE3","title":"The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"IUATLD, Inc","startDate":"2016-03","conditions":"MDR-TB","enrollment":588},{"nctId":"NCT04819906","phase":"PHASE1","title":"Effect of Estetrol Monohydrate (E4) on QTc Interval","status":"COMPLETED","sponsor":"Estetra","startDate":"2021-03-09","conditions":"Prolonged QTc Interval","enrollment":32},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT05454345","phase":"PHASE3","title":"Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-10-01","conditions":"Tuberculosis, Pulmonary","enrollment":620},{"nctId":"NCT04966325","phase":"EARLY_PHASE1","title":"Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"LG Chem","startDate":"2021-09-23","conditions":"Hyperuricemia, Gout, Qt Interval, Variation in","enrollment":37},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02114684","phase":"PHASE1, PHASE2","title":"Improving Retreatment Success (IMPRESS)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2013-11","conditions":"Recurrent Tuberculosis","enrollment":197},{"nctId":"NCT01498419","phase":"PHASE2","title":"Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2012-03","conditions":"Pulmonary Tuberculosis","enrollment":207},{"nctId":"NCT01215851","phase":"PHASE2","title":"Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2010-10","conditions":"Pulmonary Tuberculosis","enrollment":85},{"nctId":"NCT00874887","phase":"PHASE4","title":"A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-03","conditions":"Anti-biotic Resistance","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":910,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Moxifloxacin (M)","genericName":"Moxifloxacin (M)","companyName":"Global Alliance for TB Drug Development","companyId":"global-alliance-for-tb-drug-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Community-acquired bacterial pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}